Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function

T cells engineered to express chimeric antigen receptors (CAR-T cells) have shown impressive clinical efficacy in the treatment of B cell malignancies. However, the development of CAR-T cell therapies for solid tumors is hampered by the lack of truly tumor-specific antigens and poor control over T c...

Descripción completa

Detalles Bibliográficos
Autores principales: Salzer, Benjamin, Schueller, Christina M., Zajc, Charlotte U., Peters, Timo, Schoeber, Michael A., Kovacic, Boris, Buri, Michelle C., Lobner, Elisabeth, Dushek, Omer, Huppa, Johannes B., Obinger, Christian, Putz, Eva M., Holter, Wolfgang, Traxlmayr, Michael W., Lehner, Manfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7441178/
https://www.ncbi.nlm.nih.gov/pubmed/32820173
http://dx.doi.org/10.1038/s41467-020-17970-3

Ejemplares similares

Ejemplares similares